Document Detail


Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer.
MedLine Citation:
PMID:  25364456     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The aim of the present study was to evaluate the safety and efficacy of administering cytokine-induced killer cells (termed allogeneic CIKs), obtained from the blood of the offspring of patients, for the treatment of non-small cell lung cancer. Symptoms, signs and laboratory assessment results for 303 cancer patients were collected prior to and following treatment with autologous or allogeneic CIKs. In addition, 54 patients with advanced non-small cell lung cancer (NSCLC) were enrolled and divided into allogeneic CIK and optimal support groups (n=27 per group) according to gender, age, Karnofsky performance status score, TNM stage and histological type. In addition, overall survival (OS) was compared between the two groups. A total of 303 patients were treated with CIKs for 647 cycles, with 308 and 339 cycles in the autologous and allogeneic CIK groups, respectively. The mean number of CIKs in the autologous and allogeneic groups was 2.11±0.32×10(10) and 2.29±0.36×10(10), respectively, with no marked differences identified between the two groups (t=1.147; P>0.05). The predominant adverse events included insomnia, fever, nausea, vomiting and mild abdominal pain, which were found, respectively, in nine (6.8%), eight (6.0%), two (1.5%) and one (0.8%) patients receiving autologous CIKs and 11 (6.5%), 10 (5.9%), one (0.6%) and one (0.6%) patients receiving allogeneic CIKs, with no marked differences identified between the two groups (P>0.05). Adverse events were not associated with cell count, frequency or duration of treatment. Following CIK treatment, the outcomes of routine blood tests, and liver and kidney function tests, as well as immune function and electrocardiogram examinations remained unchanged (P>0.05). The median OS was 11.0 months (95% confidence interval (CI), 8.6-13.4 months) and 8.0 months (95% CI, 5.3-10.7 months) for NSCLC patients receiving allogeneic CIKs and optimal support, respectively; a statistically significant difference was identified (χ(2)=5.618; P=0.018). The present study demonstrated that CIKs from human leukocyte antigen haploidentical donors are safe and prolong the survival of NSCLC patients.
Authors:
Shiyong Wang; Hui Zhang; Chang Liu; Xue Jiao; Dijie Liu; Weili DU; Ying He; Zhe Zhang; Xiuyan Wu; Jialing Wang; Chunyan Liang; Lu Zhang; Shu Liu
Related Documents :
25446376 - Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a...
25262426 - Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistan...
25234436 - Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatm...
2669626 - Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.
17888196 - Significance of pre-epiglottic space invasion in supracricoid partial laryngectomy with...
6271386 - Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophospha...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-9-24
Journal Detail:
Title:  Oncology letters     Volume:  8     ISSN:  1792-1074     ISO Abbreviation:  Oncol Lett     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-11-3     Completed Date:  -     Revised Date:  2014-11-5    
Medline Journal Info:
Nlm Unique ID:  101531236     Medline TA:  Oncol Lett     Country:  -    
Other Details:
Languages:  ENG     Pagination:  2727-2733     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cantharidin induces G2/M phase arrest and apoptosis in human gastric cancer SGC-7901 and BGC-823 cel...
Next Document:  Pancreatic schwannoma: A case report and review of the literature.